AI-powered spatial biomarker discovery company PredxBio announced on Monday that it has formed a strategic collaboration with Hamamatsu Photonics K.K., a Japanese imaging technology specialist.

This partnership combines Hamamatsu's advanced MoxiePlex multiplex immunofluorescence imaging system with PredxBio's SpaceIQ spatial analytics platform to deliver an integrated workflow for basic and translational research tailored to immuno-oncology.

Launched in late 2024, Hamamatsu's MoxiePlex is a research use only platform that captures up to 10 fluorescent markers simultaneously, enabling precise spatial mapping of proteins on cancer and immune cells within the tumour microenvironment. Designed to support the complex needs of spatial proteomics research while maintaining workflow simplicity, MoxiePlex may in the future be developed for clinical applications, especially in areas like immunotherapy response profiling.

By combining the high-resolution imaging capabilities of MoxiePlex with the explainable, multi-modal analytics of SpaceIQ, the joint offering creates a streamlined, plug-and-play ecosystem. Researchers can move from image capture to actionable insights -- such as spatial immune cell profiling, pathway activation analysis, and biomarker stratification -- with advanced speed, clarity and scalability.

PredxBio and Hamamatsu say that they are jointly committed to simplifying spatial workflows while enhancing biological resolution. The integration supports spatially resolved proteomic data in support of translational research, biomarker validation and clinical trial optimisation.